«Archives of Virology» (SCI)、«Viruses » (SCI)、«Frontiers in Cellular and Infection Microbiology» 编委
长期从事RNA病毒（流感、冠状病毒等）致病机制研究和抗病毒药物疫苗研发。在RNA病毒研究中取得系列进展，发现了一种全新的宿主因子靶点广谱抗病毒、抗炎双效抑制剂，推进1个老药品种进入多国新冠治疗的临床试验并获得英国LifeArc基金会全额资助；揭示了流感病毒促进新冠感染的分子机制；设计了基于病毒进化谱系规律的广谱新冠疫苗抗原以应对病毒变异，完成了疫苗原型产品的工艺开发，为新冠疫情防控和临床治疗提供了理论基础和候选策略。
Jiang Y#, Zhao Y#, Deng J, Wu X, Li J, Guo D, Xu K*, Qin Y*, Chen M*. Peptides targeting RAB11A-FIP2 complex inhibit HPIV3, RSV, and IAV replication as broad-spectrum antivirals. Cell Biosci. 2025 Apr 21;15(1):50.
Li S#, Ye F#, Zheng Y#, Wang J#, Peng H#, Zhu L, Chen L, Ge H, He J, Zhang B, Wu J, Zhang Z, Jiang L, Chen G, Zhao P, Lan K, Zhao Z, Qian X, Xu K*, Du Y*, Li H*, Dual-Locking the SARS-CoV-2 Spike Trimer: An Amphipathic Molecular “Bolt” Stabilizes Conserved Druggable Interfaces for Coronavirus Inhibition.Advanced Science.2025; 2417534.
Cai Z#, Ni W#,, Li W#,, Wu Z, Yao X, Zheng Y, Zhao Y, Yuan W, Liang S, Wang Q, Tang M, Chen Y, Lan K, Zhou L*, Xu K*. SARS-CoV-2 S protein disrupts the formation of ISGF3 complex through conserved S2 subunit to antagonize type I interferon response. J Virol. 2025 Jan 31;99(1):e0151624.
Jiang K #, Liang S#, Sun X *, Ben J, Qu L ,Zhang S, Chen Y, Zheng Y, Lan K, Li D*, Xu K*. Rapid inactivation of human respiratory RNA viruses by deep ultraviolet irradiation from light-emitting diodes on a high-temperature-annealed AlN/Sapphire template. Opto-Electron Adv., 230004 , 2023 Sep 27, 6(9).
Zhao Y#, Ni W#, Liang S#, Dong L#, Xiang M#, Cai Z#, Niu D#, Zhang Q, Wang D, Zheng Y, Zhang Z, Zhou D, Guo W, Pan Y, Wu X, Yang Y, Jing Z, Jiang Y, Chen Y, Yan H, Zhou Y, Xu K*, Lan K*. Vaccination with Span, an antigen guided by SARS-CoV-2 S protein evolution, protects against challenge with viral variants in mice. Sci Transl Med. 2023 Jan 4;15(677):eabo3332.
Zheng Y, Song K, Cai K, Liu L, Tang D, Long W, Zhai B, Chen J, Tao Y, Zhao Y, Liang S, Huang Q, Liu Q, Zhang Q, Chen Y, Liu Y, Li H, Wang P, Lan K, Liu H*, Xu K*. B-Cell-Epitope-Based Fluorescent Quantum Dot Biosensors for SARS-CoV-2 Enable Highly Sensitive COVID-19 Antibody Detection. Viruses. 2022 May 12;14(5):1031.
Zheng Y, Li S, Song K, Ye J, Li W, Zhong Y, Feng Z, Liang S, Cai Z, Xu K*. A Broad Antiviral Strategy: Inhibitors of Human DHODH Pave the Way for Host-Targeting Antivirals against Emerging and Re-Emerging Viruses. Viruses. 2022 Apr 28;14(5):928.
Bai L, Zhao Y, Dong J, Liang S, Guo M, Liu X, Wang X, Huang Z, Sun X, Zhang Z, Dong L, Liu Q, Zheng Y, Niu D, Xiang M, Song K, Ye J, Zheng W, Tang Z, Tang M, Zhou Y, Shen C, Dai M, Zhou L, Chen Y, Yan H, Lan K*, Xu K*. Coinfection with influenza A virus enhances SARS-CoV-2 infectivity. Cell Res.2021 Apr;31(4):395-403.
Xiong R, Zhang L, Li S, Sun Y, Ding M, Wang Y, Zhao Y, Wu Y, Shang W, Jiang X, Shan J, Shen Z, Tong Y, Xu L, Chen Y, Liu Y, Zou G, Lavillete D, Zhao Z, Wang R, Zhu L, Xiao G, Lan K, Li H*, Xu K*. Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2. Protein&Cell. 2020 ct;11(10):723-739.
Hu K*, Wang M, Zhao Y, Zhang Y, Wang T, Zheng Z, Li X, Zeng S, Zhao D, Li H, Xu K*, Lan K*. A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial. Virol Sin. 2020 Jul, 35(6):725-733.
